This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Intracoronary cardiosphere-derived cells after myocardial infarction: evidence for therapeutic regeneration in the final 1-year results of the CADUCEUS trial.
This paper describes the 1-year results of the CADUCEUS randomized trial on the effect of intracoronary delivery of cardiosphere derived cells (CDC) 1.5 to 3 months after myocardial infarction. Safety endpoints were similar in both groups. Patients treated with CDC had smaller scar size, an increase in viable myocardium and improved regional function of infarcted myocardium than those in the control group. Global ventricular function did not change from baseline to follow up in either group.